{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:10:17Z","timestamp":1770743417940,"version":"3.49.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T00:00:00Z","timestamp":1427673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0122047","type":"journal-article","created":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T12:49:53Z","timestamp":1427806193000},"page":"e0122047","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review"],"prefix":"10.1371","volume":"10","author":[{"given":"Weixin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiandong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Chaftari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Cruz Carreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Viets-Upchurch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Merriman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ming","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Ching J.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,3,30]]},"reference":[{"issue":"24","key":"ref1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"EM Messing","year":"1999","journal-title":"The New England journal of medicine"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer","volume":"63","author":"MR Smith","year":"2004","journal-title":"Urology"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"MR Smith","year":"2002","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1464-410X.2010.09679.x","article-title":"A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"107","author":"HS Kim","year":"2011","journal-title":"BJU international"},{"issue":"15","key":"ref5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"IF Tannock","year":"2004","journal-title":"The New England journal of medicine"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"DP Petrylak","year":"2004","journal-title":"The New England journal of medicine"},{"key":"ref7","unstructured":"Pazdur R. FDA Approval for Docetaxel. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-docetaxel\" xlink:type=\"simple\">http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-docetaxel<\/ext-link> USA2013 [updated 07\/02\/2013]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-docetaxel\" xlink:type=\"simple\">http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-docetaxel<\/ext-link>."},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"PL Kellokumpu-Lehtinen","year":"2013","journal-title":"The lancet oncology"},{"issue":"20","key":"ref9","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-06-0200","article-title":"Pharmacokinetics and toxicity of weekly docetaxel in older patients","volume":"12","author":"A Hurria","year":"2006","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"4 Suppl 15","key":"ref10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0093-7754(01)90149-6","article-title":"Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate","volume":"28","author":"W Berry","year":"2001","journal-title":"Seminars in oncology"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000078328","article-title":"A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer","volume":"66","author":"JM Ferrero","year":"2004","journal-title":"Oncology"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1158\/1078-0432.CCR-0842-03","article-title":"Comparative pharmacokinetics of weekly and every-three-weeks docetaxel","volume":"10","author":"SD Baker","year":"2004","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"24","key":"ref13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","article-title":"Role of body surface area in dosing of investigational anticancer agents in adults, 1991\u20132001","volume":"94","author":"SD Baker","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200645030-00002","article-title":"Clinical pharmacokinetics of docetaxel: recent developments","volume":"45","author":"SD Baker","year":"2006","journal-title":"Clinical pharmacokinetics"},{"issue":"30","key":"ref15","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1200\/JCO.2007.11.2938","article-title":"Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese","volume":"25","author":"A Sparreboom","year":"2007","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"CM Prado","year":"2007","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment","volume":"15","author":"CM Prado","year":"2009","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"12","key":"ref18","first-page":"5655","article-title":"A higher body mass index and fat mass are factors predictive of docetaxel dose intensity","volume":"33","author":"S Gouerant","year":"2013","journal-title":"Anticancer research"},{"issue":"13","key":"ref19","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"JJ Griggs","year":"2012","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0022-5347(01)66160-3","article-title":"Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting","volume":"155","author":"JW Moul","year":"1996","journal-title":"J Urol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"Journal of chronic diseases"},{"issue":"5","key":"ref22","first-page":"303","article-title":"A formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"D Du Bois","year":"1989","journal-title":"Nutrition"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"e41883","DOI":"10.1371\/journal.pone.0041883","article-title":"The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer","volume":"7","author":"CH Richards","year":"2012","journal-title":"PloS one"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"L Martin","year":"2013","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image","volume":"97","author":"W Shen","year":"2004","journal-title":"Journal of applied physiology"},{"key":"ref26","first-page":"1","author":"R Dobbs","year":"2014"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","article-title":"Obesity and prostate cancer: weighing the evidence","volume":"63","author":"EH Allott","year":"2013","journal-title":"European urology"},{"issue":"25","key":"ref28","first-page":"iv255","article-title":"Impact of body composition on treatment toxicities in patients with metastatic prostate cancer treated with docetaxel","volume":"25","author":"S Cushen","year":"2014","journal-title":"Annals of Oncology"},{"issue":"13","key":"ref29","first-page":"1191","article-title":"Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center","volume":"1","author":"KA Hotchkiss","year":"2002","journal-title":"Molecular cancer therapeutics"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/152581602753448577","article-title":"Docetaxel versus paclitaxel for antiangiogenesis","volume":"11","author":"A Vacca","year":"2002","journal-title":"Journal of hematotherapy & stem cell research"},{"issue":"9","key":"ref31","first-page":"706","article-title":"Influence of obesity on drug disposition","volume":"6","author":"RA Blouin","year":"1987","journal-title":"Clinical pharmacy"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"MJ Hanley","year":"2010","journal-title":"Clinical pharmacokinetics"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JOP.200016","article-title":"Description of current practices of empiric chemotherapy dose adjustment in obese adult patients","volume":"6","author":"LA Thompson","year":"2010","journal-title":"Journal of oncology practice \/ American Society of Clinical Oncology"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/clpt.2014.3","article-title":"To cap or not to cap: chemotherapy dosing in obese adult hematology patients","volume":"95","author":"G Sandhu","year":"2014","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"8","key":"ref35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrclinonc.2013.108","article-title":"Chemotherapy dosing in overweight and obese patients with cancer","volume":"10","author":"GH Lyman","year":"2013","journal-title":"Nature reviews Clinical oncology"},{"issue":"30","key":"ref36","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1200\/JCO.2007.13.1078","article-title":"Obesity in dose calculation: a mouse or an elephant?","volume":"25","author":"H Gurney","year":"2007","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11605-012-2045-9","article-title":"Visceral obesity and colorectal cancer: are we missing the boat with BMI?","volume":"17","author":"AS Rickles","year":"2013","journal-title":"Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jamcollsurg.2013.01.007","article-title":"Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation","volume":"216","author":"W Clark","year":"2013","journal-title":"Journal of the American College of Surgeons"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/gutjnl-2013-304701","article-title":"Obesity and colorectal cancer","volume":"62","author":"M Bardou","year":"2013","journal-title":"Gut"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1634\/theoncologist.2012-0169","article-title":"The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer","volume":"17","author":"E Del Fabbro","year":"2012","journal-title":"The oncologist"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0122047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T08:35:47Z","timestamp":1540024547000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0122047"}},"subtitle":[],"editor":[{"given":"Raul M.","family":"Luque","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,30]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0122047","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,30]]}}}